Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR April 7, 2024
Pyxis Oncology Provides Corporate Update and Reports Financial Results for Fourth Quarter and Full Year 2023 March 25, 2024
Engrail closes $157M series B, fueled by investors’ renewed interest in neuropsychiatry March 19, 2024
Engrail Therapeutics Closes Oversubscribed $157M Series B Financing Round to Advance the Development of Transformational Therapies March 19, 2024
KalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey March 19, 2024
